

# HEALTHY U CHIP

## PRIOR AUTHORIZATION REQUEST FORM

### OSTEOPOROSIS MEDICATIONS

Evenity®, teriparatide, Tymlos®

**For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

**Preferred:**  Evenity® (romosozumab),  teriparatide,  Tymlos® (abaloparatide)

Dosing/Frequency: \_\_\_\_\_

#### If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Does the member have a documented diagnosis of one of the following: <ul style="list-style-type: none"> <li>• Postmenopausal female with osteoporosis,</li> <li>• Male with primary or hypogonadal osteoporosis,</li> <li>• Osteoporosis likely caused by systemic glucocorticoid therapy?</li> </ul>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. Is the member considered high risk for fracture, defined by meeting one of the following: <ul style="list-style-type: none"> <li>• History of recent fragility fracture or bone mineral density measurement showing osteoporosis (T-score <math>\leq</math> -2.5),</li> <li>• History of previous fractures and/or glucocorticoid use for at least 3 months and osteopenia (T-Score between -1 and -2.5)?</li> </ul>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Does the member have severe osteoporosis, defined as one of the following: <ul style="list-style-type: none"> <li>• T-score <math>\leq</math> -2.5 plus a recent fragility fracture</li> <li>• T-score <math>\leq</math> -3.5 and at high risk for fragility fracture based on FRAX score</li> </ul>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Does documentation show a 24-month trial and failure (defined as progression of bone loss) of at least one bisphosphonate (i.e.	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

alendronate, ibandronate, risedronate, intravenous zoledronic acid), unless contraindicated? <ul style="list-style-type: none"> <li>• IV therapy (zoledronic acid) is required if the member is unable to tolerate oral bisphosphonate or has an absorption disorder.</li> </ul>			
5. Does documentation show a 24-month trial and failure of Prolia®, unless contraindicated?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician's Signature:			

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-CHIP-054  
 Origination Date: 07/01/2024  
 Reviewed/Revised Date: 08/29/2024  
 Next Review Date: 08/29/2025  
 Current Effective Date: 09/01/2024

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.